{"a":[{"_":"Increased deaths shadow AstraZeneca, Daiichi’s Enhertu first-line lung cancer data","$":{"href":"/pharma/higher-death-risk-shadows-astrazeneca-daiichi-enhertu-first-line-lung-cancer-data","hreflang":"en"}}]}
Phase 3negativeEnhertuNegative
AI Analysis
Summary
AstraZeneca and Daiichi Sankyo's Enhertu faces a significant setback in its phase 3 trial for first-line HER2-mutant non-small cell lung cancer, with a preliminary 15% higher death risk threatening the drug's regulatory path.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Preliminary 15% higher death risk observed in phase 3 trial
Importance:8/10
Sentiment:
-0.85
ADConcologylung cancerHER2-mutantsafety concernphase 3first-line treatment
Read the original article
Published by FiercePharma on September 11, 2026 10:07 AM